Literature DB >> 21244352

Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles.

G T Lesser1, M S Beeri, J Schmeidler, D P Purohit, V Haroutunian.   

Abstract

UNLABELLED: Elevated serum total cholesterol (TC) has been considered a risk factor for Alzheimer's disease (AD), but conflicting results have confused understanding of the relationships of serum lipids to the presence of AD in the elderly.
METHODS: To clarify these issues, we evaluated correlations of admission TC, low-density (LDL) and high-density (HDL)cholesterol directly with the densities of Alzheimer hallmarks--neuritic plaques (NP) and neurofibrillary tangles (NFT)--in nursing home residents (n=281).
RESULTS: Significant positive associations of TC and LDL with NP densities were found in both the neocortex (TC: r=0.151, p=0.013 and LDL: r=0.190, p=0.005) and the hippocampal/entorhinal (allocortical)region (TC: r=0.182, p=0.002 and LDL: r=0.203, p=0.003). Associations of HDL with NP were less strong but also significant.In contrast, after adjustment for confounders, no correlations of NFT with any lipid were significant.When subjects with any non-AD neuropathology (largely vascular) were excluded, the TC-plaque and LDL-plaque associations for the remaining "Pure AD" subgroup were consistently stronger than for the full sample. The TC- and LDL-plaque correlations were also stronger for the subgroup of 87 subjects with an APOE ε4 allele.
CONCLUSIONS: The findings indicate that serum TC and LDL levels clearly relate to densities of NP, but not to densities of NFT. The stronger associations found in the subgroup that excluded all subjects with non-AD neuropathology suggest that cerebrovascular involvement does not explain these lipid-plaque relationships. Since the associations of TC/LDL with NP were particularly stronger in ε4 carriers, varying prevalence of this allele may explain some discrepancies among prior studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21244352      PMCID: PMC3267087          DOI: 10.2174/156720511795563755

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  103 in total

1.  Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study.

Authors:  Lon White; Brent J Small; Helen Petrovitch; G Webster Ross; Kamal Masaki; Robert D Abbott; John Hardman; Daron Davis; James Nelson; William Markesbery
Journal:  J Geriatr Psychiatry Neurol       Date:  2005-12       Impact factor: 2.680

2.  Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease.

Authors:  G Li; E B Larson; J A Sonnen; J B Shofer; E C Petrie; A Schantz; E R Peskind; M A Raskind; J C S Breitner; T J Montine
Journal:  Neurology       Date:  2007-08-28       Impact factor: 9.910

Review 3.  Cholesterol involvement in the pathogenesis of neurodegenerative diseases.

Authors:  Jun-Ping Liu; Ying Tang; Shufeng Zhou; Ban Hock Toh; Catriona McLean; He Li
Journal:  Mol Cell Neurosci       Date:  2009-08-04       Impact factor: 4.314

Review 4.  Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease.

Authors:  Rashid Deane; Berislav V Zlokovic
Journal:  Curr Alzheimer Res       Date:  2007-04       Impact factor: 3.498

5.  Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model.

Authors:  L M Refolo; B Malester; J LaFrancois; T Bryant-Thomas; R Wang; G S Tint; K Sambamurti; K Duff; M A Pappolla
Journal:  Neurobiol Dis       Date:  2000-08       Impact factor: 5.996

6.  High total cholesterol levels in late life associated with a reduced risk of dementia.

Authors:  M M Mielke; P P Zandi; M Sjögren; D Gustafson; S Ostling; B Steen; I Skoog
Journal:  Neurology       Date:  2005-05-24       Impact factor: 9.910

Review 7.  Cholesterol, lipids, amyloid Beta, and Alzheimer's.

Authors:  Mun'delanji Vestergaard; Tsutomu Hamada; Masamune Morita; Masahiro Takagi
Journal:  Curr Alzheimer Res       Date:  2010-05       Impact factor: 3.498

8.  Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease.

Authors:  T Gomez-Isla; H L West; G W Rebeck; S D Harr; J H Growdon; J J Locascio; T T Perls; L A Lipsitz; B T Hyman
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

9.  Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition.

Authors:  Yongmei Liu; Josef Coresh; Joseph A Eustace; J Craig Longenecker; Bernard Jaar; Nancy E Fink; Russell P Tracy; Neil R Powe; Michael J Klag
Journal:  JAMA       Date:  2004-01-28       Impact factor: 56.272

10.  Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production.

Authors:  Huaqi Xiong; Debbie Callaghan; Aimee Jones; Douglas G Walker; Lih-Fen Lue; Thomas G Beach; Lucia I Sue; John Woulfe; Huaxi Xu; Danica B Stanimirovic; Wandong Zhang
Journal:  Neurobiol Dis       Date:  2007-11-04       Impact factor: 5.996

View more
  16 in total

1.  Association between Cholesterol Exposure and Neuropathological Findings: The ACT Study.

Authors:  Brianne M Bettcher; M Colin Ard; Bruce R Reed; Andreana Benitez; Amanda Simmons; Eric B Larson; Josh A Sonnen; Thomas J Montine; Ge Li; C Dirk Keene; Paul K Crane; Dan Mungas
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

2.  Age-related differences in memory and executive functions in healthy APOE ɛ4 carriers: the contribution of individual differences in prefrontal volumes and systolic blood pressure.

Authors:  Andrew R Bender; Naftali Raz
Journal:  Neuropsychologia       Date:  2012-01-10       Impact factor: 3.139

3.  Association of Hypercholesterolemia with Alzheimer's Disease Pathology and Cerebral Amyloid Angiopathy.

Authors:  Chenjia Xu; Liana G Apostolova; Adrian L Oblak; Sujuan Gao
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

4.  Lipids and adipokines as risk factors for Alzheimer's disease.

Authors:  Matthew W Warren; Linda S Hynan; Myron F Weiner
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

5.  Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease.

Authors:  Julie M Zissimopoulos; Douglas Barthold; Roberta Diaz Brinton; Geoffrey Joyce
Journal:  JAMA Neurol       Date:  2017-02-01       Impact factor: 18.302

6.  Caffeine, Through Adenosine A3 Receptor-Mediated Actions, Suppresses Amyloid-β Protein Precursor Internalization and Amyloid-β Generation.

Authors:  Shanshan Li; Nicholas H Geiger; Mahmoud L Soliman; Liang Hui; Jonathan D Geiger; Xuesong Chen
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

7.  Associations between serum cholesterol levels and cerebral amyloidosis.

Authors:  Bruce Reed; Sylvia Villeneuve; Wendy Mack; Charles DeCarli; Helena C Chui; William Jagust
Journal:  JAMA Neurol       Date:  2014-02       Impact factor: 18.302

8.  Early adult to midlife cardiovascular risk factors and cognitive function.

Authors:  Kristine Yaffe; Eric Vittinghoff; Mark J Pletcher; Tina D Hoang; Lenore J Launer; Rachel Whitmer; Laura H Coker; Stephen Sidney
Journal:  Circulation       Date:  2014-03-31       Impact factor: 39.918

Review 9.  Potential biomarkers in psychiatry: focus on the cholesterol system.

Authors:  Alisa G Woods; Izabela Sokolowska; Regina Taurines; Manfred Gerlach; Edward Dudley; Johannes Thome; Costel C Darie
Journal:  J Cell Mol Med       Date:  2012-06       Impact factor: 5.310

10.  Association studies of several cholesterol-related genes (ABCA1, CETP and LIPC) with serum lipids and risk of Alzheimer's disease.

Authors:  Zhijie Xiao; Juan Wang; Weirong Chen; Peng Wang; Houlin Zeng; Weixi Chen
Journal:  Lipids Health Dis       Date:  2012-11-26       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.